The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma-Reference-Cited by-同舟云学术

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

Published:2022-03 Issue:3 Volume:33 Page:288-298
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Horwitz S.,O'Connor O.A.,Pro B.,Trümper L.,Iyer S.,Advani R.,Bartlett N.L.,Christensen J.H.,Morschhauser F.,Domingo-Domenech E.,Rossi G.,Kim W.S.,Feldman T.,Menne T.,Belada D.,Illés Á.,Tobinai K.,Tsukasaki K.,Yeh S.-P.,Shustov A.,Hüttmann A.,Savage K.J.,Yuen S.,Zinzani P.L.,Miao H.,Bunn V.,Fenton K.,Fanale M.,Puhlmann M.,Illidge T.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference37 articles.

1. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes;Vose;J Clin Oncol,2008

2. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project;Savage;Blood,2008

3. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma;Chihara;Br J Haematol,2017

4. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry;Ellin;Blood,2014

5. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-cell Project;Bellei;Haematologica,2018

Cited by 134 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Yttrium-90 anti-CD25 BEAM conditioning for autologous hematopoietic cell transplantation in Peripheral T-cell lymphoma;Blood Advances;2024-09-24

2. Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study;The Lancet Haematology;2024-09

3. Targeted agents plus CHOP compared with CHOP as the first-line treatment for newly diagnosed patients with peripheral T-cell lymphoma (GUIDANCE-03): an open-label, multicentre phase 2 clinical trial;The Lancet Regional Health - Western Pacific;2024-09

4. Next Questions in Peripheral T-Cell Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2024-09

5. Optimizing Frontline Treatment for PTCL;Clinical Lymphoma Myeloma and Leukemia;2024-09